Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Arcellx, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/07/2023 |
4
| Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 3,000 shares
@ $35.3778, valued at
$106.1k
Exercised 3,000 options to buy
@ $15, valued at
$45k
|
|
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/21/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/05/2023 |
4
| Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 3,000 shares
@ $31.7487, valued at
$95.2k
Exercised 3,000 options to buy
@ $15, valued at
$45k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/16/2023 |
4
| Carroll Jill (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/16/2023 |
4
| Behbahani Ali (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/16/2023 |
4
| Yoon Derek (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/16/2023 |
4
| Ware Olivia C (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/16/2023 |
4
| Patel Kavita (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/16/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Granted 11,459 options to buy
@ $37.94, valued at
$434.8k
|
|
| 06/05/2023 |
4
| Behbahani Ali (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Acquired 113 shares
@ $0
Acquired 28 shares
@ $0 |
|
| 06/02/2023 |
4
| Elghandour Rami (See Remarks) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 2,600 shares
@ $44.2688, valued at
$115.1k
|
|
| 06/02/2023 |
4
| Carroll Jill (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 315,164 shares
@ $41.5, valued at
$13.1M
Sold 25,556 shares
@ $44.3464, valued at
$1.1M
|
|
| 06/02/2023 |
SC 13D/A
| SR ONE CAPITAL MANAGEMENT, LLC reports a 8.2% stake in Arcellx, Inc. |
| 05/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/25/2023 |
4
| Gilson Michelle (CFO) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 8,554 shares
@ $42.47, valued at
$363.3k
Sold 150 shares
@ $41.64, valued at
$6.2k
Sold 6,000 shares
@ $42.7694, valued at
$256.6k
Exercised 22,428 restricted stock units
@ $0 |
|
| 05/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/19/2023 |
SC 13D/A
| SR ONE CAPITAL MANAGEMENT, LLC reports a 9.4% stake in Arcellx, Inc. |
| 05/15/2023 |
4
| Carroll Jill (Director) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 631,932 shares
@ $45, valued at
$28.4M
Sold 6,485 shares
@ $46.15, valued at
$299.3k
|
|
| 05/15/2023 |
4
| SR ONE CAPITAL MANAGEMENT, LLC (10% Owner) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 631,932 shares
@ $45, valued at
$28.4M
Sold 370,612 shares
@ $45, valued at
$16.7M
Sold 6,485 shares
@ $46.15, valued at
$299.3k
Sold 3,804 shares
@ $46.15, valued at
$175.6k
|
|
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/11/2023 |
4
| Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 500 shares
@ $45, valued at
$22.5k
Sold 2,197 shares
@ $45.1824, valued at
$99.3k
|
|
| 05/09/2023 |
10-Q/A
| Quarterly Report for the period ended March 31, 2023 [amend] |
| 05/08/2023 |
4
| Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 1,200 shares
@ $45.0017, valued at
$54k
|
|
| 05/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/08/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/08/2023 |
8-K
| Quarterly results|
Docs:
|
"Arcellx Provides First Quarter Financial Results REDWOOD CITY, Calif., May 8, 2023 /PRNewswire/ -- Arcellx, Inc. , a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the first quarter ended March 31, 2023. “Delivering our novel CAR-T therapy to multiple myeloma patients is at the heart of our mission,” said Rami Elghandour, Arcellx’s Chairman and Chief Executive Officer. “With the closing of our Kite partnership in the first quarter, we believe we are well capitalized to fund our operations through the first half of 2025. We remain laser-focused on key drivers of our business which include completing enrollment of iMMagine-1, i..." |
|
| 05/05/2023 |
4
| Heery Christopher (Chief Medical Officer) has filed a Form 4 on Arcellx, Inc.|
Txns:
| Sold 400 shares
@ $42.715, valued at
$17.1k
Sold 2,600 shares
@ $43.5551, valued at
$113.2k
Exercised 3,000 options to buy
@ $15, valued at
$45k
|
|
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
|
|
|